INTRODUCTION: The present study was designed to assess the antidepressant effects of UFP-101, a selective nociceptin/orphanin FQ peptide (NOP) receptor antagonist, in a validated animal model of depression: the chronic mild stress (CMS). MATERIALS AND METHODS AND RESULTS: UFP-101 (5, 10 and 20 nmol/rat; i.c.v., once a day for 21 days) dose- and time-dependently reinstated sucrose consumption in stressed animals without affecting the same parameter in non-stressed ones. In the forced swimming test, UFP-101 reduced immobility of stressed rats from day 8 of treatment. After a 3-week treatment, rats were killed for biochemical evaluations. UFP-101 abolished increase in serum corticosterone induced by CMS and reverted changes in central 5-HT/5-HIAA ratio. The behavioural and biochemical effects of UFP-101 mimicked those of imipramine, the reference antidepressant drug, administered at the dose of 15 mg/kg (i.p.). Co-administration of nociceptin/orphanin FQ (5 nmol/rat, from day 12 to 21) prevented the effects of UFP-101. Brain-derived neurotrophic factor mRNA and protein in hippocampus were not reduced by CMS nor did UFP-101 modify these parameters. DISCUSSION AND CONCLUSION: This study demonstrated that chronic treatment with UFP-101 produces antidepressant-like effects in rats subjected to CMS supporting the proposal that NOP receptors represent a candidate target for the development of innovative antidepressant drugs.
INTRODUCTION: The present study was designed to assess the antidepressant effects of UFP-101, a selective nociceptin/orphanin FQ peptide (NOP) receptor antagonist, in a validated animal model of depression: the chronic mild stress (CMS). MATERIALS AND METHODS AND RESULTS: UFP-101 (5, 10 and 20 nmol/rat; i.c.v., once a day for 21 days) dose- and time-dependently reinstated sucrose consumption in stressed animals without affecting the same parameter in non-stressed ones. In the forced swimming test, UFP-101 reduced immobility of stressed rats from day 8 of treatment. After a 3-week treatment, rats were killed for biochemical evaluations. UFP-101 abolished increase in serum corticosterone induced by CMS and reverted changes in central 5-HT/5-HIAA ratio. The behavioural and biochemical effects of UFP-101 mimicked those of imipramine, the reference antidepressant drug, administered at the dose of 15 mg/kg (i.p.). Co-administration of nociceptin/orphanin FQ (5 nmol/rat, from day 12 to 21) prevented the effects of UFP-101. Brain-derived neurotrophic factor mRNA and protein in hippocampus were not reduced by CMS nor did UFP-101 modify these parameters. DISCUSSION AND CONCLUSION: This study demonstrated that chronic treatment with UFP-101 produces antidepressant-like effects in rats subjected to CMS supporting the proposal that NOP receptors represent a candidate target for the development of innovative antidepressant drugs.
Authors: E C Gavioli; C W Vaughan; G Marzola; R Guerrini; V A Mitchell; S Zucchini; T C M De Lima; G A Rae; S Salvadori; D Regoli; G Calo' Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2004-05-25 Impact factor: 3.000
Authors: Matthew N Hill; Kim G C Hellemans; Pamela Verma; Boris B Gorzalka; Joanne Weinberg Journal: Neurosci Biobehav Rev Date: 2012-07-07 Impact factor: 8.989
Authors: Aldemara I Silva; Victor A D Holanda; Joaquim G Azevedo Neto; Edilson D Silva Junior; Vanessa P Soares-Rachetti; Girolamo Calo; Chiara Ruzza; Elaine C Gavioli Journal: Psychopharmacology (Berl) Date: 2020-02-24 Impact factor: 4.530
Authors: Victor A D Holanda; Iris U Medeiros; Laila Asth; Remo Guerrini; Girolamo Calo'; Elaine C Gavioli Journal: Psychopharmacology (Berl) Date: 2016-04-30 Impact factor: 4.530